{"id":"NCT00320398","sponsor":"GlaxoSmithKline","briefTitle":"Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)","officialTitle":"Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01-30","primaryCompletion":"2006-07-18","completion":"2006-07-18","firstPosted":"2006-05-03","resultsPosted":"2017-12-21","lastUpdate":"2018-09-04"},"enrollment":114,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":null,"primaryPurpose":"PREVENTION"},"conditions":["Thrombosis, Venous"],"interventions":[{"type":"DRUG","name":"Fondaparinux","otherNames":[]}],"arms":[],"summary":"This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).","primaryOutcome":{"measure":"Percentage of Participants With Venous Thromboembolism (VTE) During Efficacy Period","timeFrame":"Up to Day 17","effectByArm":[{"arm":"Fondaparinux 1.5 mg","deltaMin":8.3,"sd":null},{"arm":"Fondaparinux 2.5 mg","deltaMin":2.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":58},"commonTop":["Myalgia","Insomnia","Constipation","Pruritus","Platelet count increased"]}}